SCHEMBL6514840

SCHEMBL6514840

Cc1c2c(=O)n(CCCN3C(=O)c4ccccc4C3=O)c3c(Br)cc(Cl)cc3c2nn1C1CCCCO1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
DRD1 P21728 1/20 0.33
MEN1 O00255 4/20 0.33
MAPT P10636 3/20 0.33
LMNA P02545 3/20 0.33
RXFP1 Q9HBX9 1/20 0.33
KDM4E B2RXH2 3/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
HTR4 Q13639 1/20 0.31
TP53 P04637 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
CYP1B1 Q16678 3/20 0.31
ALDH1A1 P00352 2/20 0.31
HTR1A P08908 1/20 0.31
HTR7 P34969 1/20 0.31
HRH1 P35367 1/20 0.31
DRD3 P35462 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6515376 0.87 MAPT (0.41) KMT2ASMN1; SMN2DRD1MEN1MAPT
SCHEMBL6514298 0.82 RET (0.34)
SCHEMBL6514337 0.80 PGK1 (0.37) DRD1CYP1A2CYP2C9CYP2C19
SCHEMBL6517507 0.76 CHEK1 (0.50) KMT2ASMN1; SMN2MEN1MAPTLMNA
SCHEMBL6517970 0.75 CHEK1 (0.36)
SCHEMBL6509485 0.74 GAA (0.36) LMNAALDH1A1POLB
SCHEMBL6511094 0.70 CHEK1 (0.41) KMT2ASMN1; SMN2MAPTLMNAKDM4E
SCHEMBL6514165 0.69 CHEK1 (0.39) KMT2ASMN1; SMN2MAPTLMNAKDM4E
SCHEMBL6522000 0.69 CHEK1 (0.41) KMT2AMAPTLMNAKDM4ECYP1A2
SCHEMBL6511866 0.69 CHEK1 (0.38) KMT2ASMN1; SMN2MAPTLMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050245563-A1 Chk-1 inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-11-03 US disclosed
WO-2005028474-A2 PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245563-A1 Chk-1 inhibitors CHKA, CHKB, CHEK1 KMT2A 1919/4885SMN1; SMN2 3724/4885DRD1 4838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.